Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCVAC/OvCa Maintenance in Relapsed Ovarian Cancer
NCT03657966Phase 2Completed
- Sponsor
- SOTIO Biotech
- Start
- Nov 2017
- Primary completion
- Nov 2020
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of DCVAC/OvCa in ovarian cancer, sponsored by SOTIO Biotech. Primary endpoint: Progression Free Survival at 104 weeks. Started Nov 2017; status: completed.
02
Drugs
DCVAC/OvCa
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03657966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03657966.